+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Retinal Disease Therapy Options Market - Global Forecast to 2030- Product Image
Retinal Disease Therapy Options Market - Global Forecast to 2030- Product Image
New

Retinal Disease Therapy Options Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 185 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6085119
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Retinal diseases, ranging from age-related macular degeneration to diabetic retinopathy and inherited conditions such as retinitis pigmentosa, present an escalating challenge for healthcare systems worldwide. The convergence of demographic shifts, technological breakthroughs and evolving regulatory frameworks has spurred a surge in novel therapies spanning biologics, gene modulation platforms, small molecules and advanced drug delivery systems. At the same time, advancements in diagnostic imaging-optical coherence tomography, fluorescein angiography and high-resolution ophthalmoscopy-have refined patient stratification and treatment monitoring, enabling more personalized care pathways. As the field advances, stakeholders must navigate complex dynamics that include shifting payment models, supply chain realignments and an intensifying competitive environment. This executive summary outlines the major forces reshaping retinal disease therapy, highlights critical insights derived from multi-axis segmentation, examines regional nuances and identifies the leading companies driving innovation. Finally, it presents targeted recommendations to guide industry leaders in capitalizing on emerging opportunities while mitigating risks associated with an increasingly interconnected market.

Transformative Shifts Shaping Retinal Disease Treatment Innovations

Over the past decade, the retinal disease therapy landscape has undergone a profound transformation driven by breakthroughs in molecular biology, engineering and digital health. Gene editing techniques such as CRISPR have moved from proof-of-concept into early clinical trials, offering the promise of durable correction for inherited retinal dystrophies. Simultaneously, sustained-release intravitreal implants and suprachoroidal delivery approaches have extended treatment intervals, improving patient adherence and reducing clinic visits. Artificial intelligence-enabled image analysis now accelerates diagnosis and progression monitoring, enabling earlier intervention in age-related and vascular retinopathies. Moreover, the emergence of nanotechnology has facilitated novel carriers for antioxidants and anti-inflammatories, enhancing drug stability and ocular penetration. Fueled by these advances, pharmaceutical and biotech players are forging partnerships that blend traditional angiogenesis inhibitors with next-generation modalities such as gene modulators and cell-based therapies. Consequently, the competitive landscape is shifting from incremental improvements toward truly paradigm-altering solutions, compelling established players to reassess their R&D priorities and go-to-market strategies.

Assessing the Cumulative Impact of United States Tariffs in 2025

The cumulative impact of the United States tariffs enacted in 2025 has reverberated across the retinal disease therapy supply chain, affecting APIs, biologic components and specialized ophthalmic devices. Companies importing critical raw materials-ranging from viral vectors used in gene therapies to nanoformulations-have faced higher entry costs, prompting strategic adjustments. Several manufacturers have begun relocating production closer to end markets or securing tariff exemptions through local partnerships. At the same time, distributors and clinics have absorbed cost pressures by negotiating volume-based contracts and exploring alternative suppliers. These adjustments have slowed the rollout of certain late-stage candidates, encouraging firms to re-evaluate global supply strategies and reinforce inventory buffers. Collectively, these shifts underscore the importance of supply chain resilience and cost optimization as fundamental pillars for sustaining innovation and ensuring patient access in an era of heightened trade tensions.

Key Segmentation Insights Driving Targeted Therapeutic Approaches

A multifaceted segmentation framework reveals nuanced demand patterns and priority areas for therapeutic innovation. When dissected by therapy type, interest peaks in gene therapy projects alongside established biologics, while small molecules and traditional pharmaceuticals maintain broad adoption. Examining routes of administration, intravitreal approaches-divided into implants and injections-dominate clinical development, although oral, systemic and topical formulations gain attention for their potential to reduce procedural burden. Disease type segmentation highlights intense R&D focus on age-related macular degeneration, split between dry and wet manifestations, as well as diabetic retinopathy, retinal vein occlusion and retinitis pigmentosa. Mechanism-of-action analysis shows continued reliance on angiogenesis inhibitors, complemented by anti-inflammatories, antioxidants and emerging gene modulators. From a patient demographics standpoint, geriatrics and adults represent core markets, whereas pediatric subgroups-adolescents, children and infants-require specialized dosing and safety considerations. Care settings segmentation positions clinics, hospitals, outpatient centers and home care as critical delivery environments, each with distinct resource requirements. Assessing end users emphasizes the roles of healthcare providers, patients, pharmaceutical companies and researchers in driving adoption curves. Disease staging-early, intermediate and late-guides timing of intervention, and diagnostic tools such as fluorescein angiography, ophthalmoscopy and optical coherence tomography underpin evidence-based treatment decisions. Pricing structure analysis reveals a mix of government subsidies, insurance-covered programs and self-funded models, shaping access and reimbursement strategies. Finally, clinical trial phase breakdown-preclinical through Phase III-paired with innovative technology focus areas, including artificial intelligence, CRISPR and nanotechnology, underscores the innovation pipeline’s depth and diversity.

Regional Dynamics Influencing Market Opportunities and Challenges

Regional dynamics exert a powerful influence on market entry, pricing negotiations and patient access. In the Americas, advanced reimbursement frameworks and robust clinical trial infrastructure accelerate the adoption of high-cost modalities such as gene therapies and sustained-release implants, while emerging Latin American markets seek to expand insurance coverage and local manufacturing capabilities. Across Europe, the Middle East & Africa, regulatory pathways vary significantly, with some countries offering conditional approvals and innovative payment arrangements, whereas others confront reimbursement hurdles that delay market introductions. Local health authorities are increasingly receptive to real-world evidence submissions, which benefit adaptive trial designs. In the Asia-Pacific region, strong government support for vaccine and biotech manufacturing in China, combined with Japan’s rapid uptake of advanced diagnostics, fuels growth. Markets in India and Southeast Asia prioritize cost-effective small molecules and traditional biologics, though strategic partnerships with global innovators are on the rise. Taking these regional distinctions into account allows companies to tailor market entry strategies, optimize resource allocation and forge collaborations that resonate with local stakeholders.

Leading Companies Steering Retinal Disease Therapy Advancements

A review of leading companies underscores varied strategic approaches that are shaping the competitive arena. 4D Molecular Therapeutics leverages capsid engineering to enhance retinal gene delivery, while Adverum Biotechnologies advances intravitreal anti-angiogenic gene therapies. Aerie Pharmaceuticals, now part of Alcon, integrates micro-implant technology for sustained drug release, complementing Alimera Sciences’ established intravitreal implant platform. Allergan’s integration into AbbVie has broadened its ophthalmology pipeline beyond conventional anti-VEGF agents. Astellas Pharma explores sustained-release small molecules administered systemically, and Bayer’s Eylea franchise remains a cornerstone amidst multiple label expansions. Biogen collaborates with academic centers on neuroprotective antioxidants, and Clearside Biomedical pioneers suprachoroidal routes for macular diseases. F. Hoffmann-La Roche and Genentech continue to co-develop bispecific antibodies while Novartis advances its brolucizumab portfolio. Graybug Vision focuses on long-acting injectable depots, and Kodiak Sciences investigates novel neuroprotective compounds. Ohr Pharmaceutical’s cholinergic modulators and Ophthotech’s anti-PDGF therapy illustrate persistent pursuit of combination regimens. Outlook Therapeutics works on tropomyosin kinase inhibitors, Regenera Pharma leads with small molecules targeting complement pathways, Regeneron Pharmaceuticals capitalizes on its Eylea backbone for new indications, and Santen Pharmaceutical expands distribution channels across Asia. These companies collectively drive the next wave of innovation through mergers, licensing agreements, strategic alliances and diversified R&D strategies.

Actionable Recommendations for Industry Leaders

To navigate this dynamic environment, industry leaders should prioritize investments in domestic manufacturing capacity and supply chain diversification to mitigate tariff-related disruptions. They should also accelerate collaborations that integrate artificial intelligence-driven diagnostics with innovative delivery platforms, ensuring seamless patient stratification and adherence monitoring. Embracing adaptive clinical trial designs, particularly in early and intermediate disease stages, can expedite proof-of-concept while optimizing resource allocation. Additionally, engaging payers and health authorities early to co-develop value demonstration frameworks will smooth reimbursement pathways. Finally, forging public-private partnerships and expanding patient education initiatives will bolster trust and uptake across diverse demographics, reinforcing market resilience.

Conclusion: Navigating the Future of Retinal Disease Therapies

The retinal disease therapy sector stands at the crossroads of scientific innovation and complex commercial dynamics. Advances in gene editing, sustained-release implants and precision diagnostics offer unprecedented opportunities to address unmet patient needs. However, evolving trade policies, diverse regional reimbursement landscapes and nuanced segmentation requirements demand agile strategies. By synthesizing insights across therapy types, delivery routes, disease variants, demographic profiles and market regions, stakeholders can craft differentiated value propositions that resonate with providers, patients and payers. In doing so, they will shape a future where sight-preserving interventions become more accessible, effective and sustainable.

Market Segmentation & Coverage

This research report categorizes the Retinal Disease Therapy Options Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Biologics
  • Gene Therapy
  • Pharmaceuticals
  • Small Molecules
  • Intravitreal
    • Implants
    • Injections
  • Oral
  • Systemic
  • Topical
  • Age-Related Macular Degeneration
    • Dry AMD
    • Wet AMD
  • Diabetic Retinopathy
  • Retinal Vein Occlusion
  • Retinitis Pigmentosa
  • Angiogenesis Inhibitors
  • Anti-Inflammatories
  • Antioxidants
  • Gene Modulators
  • Adults
  • Geriatrics
  • Pediatrics
    • Adolescents
    • Children
    • Infants
  • Clinics
  • Home Care
  • Hospitals
  • Outpatient Centers
  • Healthcare Providers
  • Patients
  • Pharmaceutical Companies
  • Researchers
  • Early Stage
  • Intermediate Stage
  • Late Stage
  • Fluorescein Angiography
  • Ophthalmoscopy
  • Optical Coherence Tomography
  • Government Subsidies
  • Insurance-Covered
  • Self-Funded
  • Phase I
  • Phase II
  • Phase III
  • Preclinical
  • Artificial Intelligence
  • CRISPR
  • Nanotechnology

This research report categorizes the Retinal Disease Therapy Options Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Retinal Disease Therapy Options Market to delves into recent significant developments and analyze trends in each of the following companies:

  • 4D Molecular Therapeutics
  • Adverum Biotechnologies, Inc.
  • Aerie Pharmaceuticals, Inc. (acquired by Alcon)
  • Alimera Sciences, Inc.
  • Allergan Plc (now part of AbbVie Inc.)
  • Astellas Pharma Inc.
  • Bayer AG
  • Biogen Inc.
  • Clearside Biomedical, Inc.
  • F. Hoffmann-La Roche AG
  • Genentech, Inc. (a member of the Roche Group)
  • Graybug Vision, Inc.
  • Kodiak Sciences Inc.
  • Novartis AG
  • Ohr Pharmaceutical, Inc.
  • Ophthotech Corp.
  • Outlook Therapeutics, Inc.
  • Regenera Pharma Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Retinal Disease Therapy Options Market, by Therapy Type
8.1. Introduction
8.2. Biologics
8.3. Gene Therapy
8.4. Pharmaceuticals
8.5. Small Molecules
9. Retinal Disease Therapy Options Market, by Route Of Administration
9.1. Introduction
9.2. Intravitreal
9.2.1. Implants
9.2.2. Injections
9.3. Oral
9.4. Systemic
9.5. Topical
10. Retinal Disease Therapy Options Market, by Disease Type
10.1. Introduction
10.2. Age-Related Macular Degeneration
10.2.1. Dry AMD
10.2.2. Wet AMD
10.3. Diabetic Retinopathy
10.4. Retinal Vein Occlusion
10.5. Retinitis Pigmentosa
11. Retinal Disease Therapy Options Market, by Mechanism Of Action
11.1. Introduction
11.2. Angiogenesis Inhibitors
11.3. Anti-Inflammatories
11.4. Antioxidants
11.5. Gene Modulators
12. Retinal Disease Therapy Options Market, by Patient Demographics
12.1. Introduction
12.2. Adults
12.3. Geriatrics
12.4. Pediatrics
12.4.1. Adolescents
12.4.2. Children
12.4.3. Infants
13. Retinal Disease Therapy Options Market, by Care Settings
13.1. Introduction
13.2. Clinics
13.3. Home Care
13.4. Hospitals
13.5. Outpatient Centers
14. Retinal Disease Therapy Options Market, by End Users
14.1. Introduction
14.2. Healthcare Providers
14.3. Patients
14.4. Pharmaceutical Companies
14.5. Researchers
15. Retinal Disease Therapy Options Market, by Stage Of Disease
15.1. Introduction
15.2. Early Stage
15.3. Intermediate Stage
15.4. Late Stage
16. Retinal Disease Therapy Options Market, by Diagnostic Tools
16.1. Introduction
16.2. Fluorescein Angiography
16.3. Ophthalmoscopy
16.4. Optical Coherence Tomography
17. Retinal Disease Therapy Options Market, by Pricing Structure
17.1. Introduction
17.2. Government Subsidies
17.3. Insurance-Covered
17.4. Self-Funded
18. Retinal Disease Therapy Options Market, by Clinical Trail Phases
18.1. Introduction
18.2. Phase I
18.3. Phase II
18.4. Phase III
18.5. Preclinical
19. Retinal Disease Therapy Options Market, by Innovative Technologies
19.1. Introduction
19.2. Artificial Intelligence
19.3. CRISPR
19.4. Nanotechnology
20. Americas Retinal Disease Therapy Options Market
20.1. Introduction
20.2. Argentina
20.3. Brazil
20.4. Canada
20.5. Mexico
20.6. United States
21. Asia-Pacific Retinal Disease Therapy Options Market
21.1. Introduction
21.2. Australia
21.3. China
21.4. India
21.5. Indonesia
21.6. Japan
21.7. Malaysia
21.8. Philippines
21.9. Singapore
21.10. South Korea
21.11. Taiwan
21.12. Thailand
21.13. Vietnam
22. Europe, Middle East & Africa Retinal Disease Therapy Options Market
22.1. Introduction
22.2. Denmark
22.3. Egypt
22.4. Finland
22.5. France
22.6. Germany
22.7. Israel
22.8. Italy
22.9. Netherlands
22.10. Nigeria
22.11. Norway
22.12. Poland
22.13. Qatar
22.14. Russia
22.15. Saudi Arabia
22.16. South Africa
22.17. Spain
22.18. Sweden
22.19. Switzerland
22.20. Turkey
22.21. United Arab Emirates
22.22. United Kingdom
23. Competitive Landscape
23.1. Market Share Analysis, 2024
23.2. FPNV Positioning Matrix, 2024
23.3. Competitive Analysis
23.3.1. 4D Molecular Therapeutics
23.3.2. Adverum Biotechnologies, Inc.
23.3.3. Aerie Pharmaceuticals, Inc. (acquired by Alcon)
23.3.4. Alimera Sciences, Inc.
23.3.5. Allergan Plc (now part of AbbVie Inc.)
23.3.6. Astellas Pharma Inc.
23.3.7. Bayer AG
23.3.8. Biogen Inc.
23.3.9. Clearside Biomedical, Inc.
23.3.10. F. Hoffmann-La Roche AG
23.3.11. Genentech, Inc. (a member of the Roche Group)
23.3.12. Graybug Vision, Inc.
23.3.13. Kodiak Sciences Inc.
23.3.14. Novartis AG
23.3.15. Ohr Pharmaceutical, Inc.
23.3.16. Ophthotech Corp.
23.3.17. Outlook Therapeutics, Inc.
23.3.18. Regenera Pharma Ltd.
23.3.19. Regeneron Pharmaceuticals, Inc.
23.3.20. Santen Pharmaceutical Co., Ltd.
24. ResearchAI
25. ResearchStatistics
26. ResearchContacts
27. ResearchArticles
28. Appendix

List of Figures
FIGURE 1. RETINAL DISEASE THERAPY OPTIONS MARKET MULTI-CURRENCY
FIGURE 2. RETINAL DISEASE THERAPY OPTIONS MARKET MULTI-LANGUAGE
FIGURE 3. RETINAL DISEASE THERAPY OPTIONS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY MECHANISM OF ACTION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 16. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CARE SETTINGS, 2024 VS 2030 (%)
FIGURE 18. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CARE SETTINGS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USERS, 2024 VS 2030 (%)
FIGURE 20. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USERS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY STAGE OF DISEASE, 2024 VS 2030 (%)
FIGURE 22. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY STAGE OF DISEASE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIAGNOSTIC TOOLS, 2024 VS 2030 (%)
FIGURE 24. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIAGNOSTIC TOOLS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PRICING STRUCTURE, 2024 VS 2030 (%)
FIGURE 26. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PRICING STRUCTURE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CLINICAL TRAIL PHASES, 2024 VS 2030 (%)
FIGURE 28. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CLINICAL TRAIL PHASES, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INNOVATIVE TECHNOLOGIES, 2024 VS 2030 (%)
FIGURE 30. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INNOVATIVE TECHNOLOGIES, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. AMERICAS RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 32. AMERICAS RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. UNITED STATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 34. UNITED STATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 35. ASIA-PACIFIC RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 36. ASIA-PACIFIC RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 37. EUROPE, MIDDLE EAST & AFRICA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 38. EUROPE, MIDDLE EAST & AFRICA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 39. RETINAL DISEASE THERAPY OPTIONS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 40. RETINAL DISEASE THERAPY OPTIONS MARKET, FPNV POSITIONING MATRIX, 2024


List of Tables
TABLE 1. RETINAL DISEASE THERAPY OPTIONS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INTRAVITREAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY IMPLANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INJECTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INTRAVITREAL, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY SYSTEMIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DRY AMD, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY WET AMD, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIABETIC RETINOPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY RETINITIS PIGMENTOSA, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ANGIOGENESIS INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ANTIOXIDANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY GENE MODULATORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY GERIATRICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PEDIATRICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CHILDREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INFANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY OUTPATIENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY HEALTHCARE PROVIDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PATIENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY RESEARCHERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY EARLY STAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INTERMEDIATE STAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY LATE STAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY FLUORESCEIN ANGIOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY OPHTHALMOSCOPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY OPTICAL COHERENCE TOMOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PRICING STRUCTURE, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY GOVERNMENT SUBSIDIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INSURANCE-COVERED, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY SELF-FUNDED, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CLINICAL TRAIL PHASES, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHASE I, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHASE II, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PHASE III, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INNOVATIVE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ARTIFICIAL INTELLIGENCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CRISPR, BY REGION, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY NANOTECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INTRAVITREAL, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 76. AMERICAS RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 77. AMERICAS RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 78. AMERICAS RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 79. AMERICAS RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 80. AMERICAS RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 81. AMERICAS RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 82. AMERICAS RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 83. AMERICAS RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PRICING STRUCTURE, 2018-2030 (USD MILLION)
TABLE 84. AMERICAS RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CLINICAL TRAIL PHASES, 2018-2030 (USD MILLION)
TABLE 85. AMERICAS RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INNOVATIVE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 86. AMERICAS RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INTRAVITREAL, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 92. ARGENTINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 93. ARGENTINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 94. ARGENTINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 95. ARGENTINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 96. ARGENTINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 97. ARGENTINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 98. ARGENTINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 99. ARGENTINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PRICING STRUCTURE, 2018-2030 (USD MILLION)
TABLE 100. ARGENTINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CLINICAL TRAIL PHASES, 2018-2030 (USD MILLION)
TABLE 101. ARGENTINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INNOVATIVE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 102. BRAZIL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 103. BRAZIL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 104. BRAZIL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INTRAVITREAL, 2018-2030 (USD MILLION)
TABLE 105. BRAZIL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 106. BRAZIL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 107. BRAZIL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 108. BRAZIL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 109. BRAZIL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 110. BRAZIL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 111. BRAZIL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 112. BRAZIL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 113. BRAZIL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PRICING STRUCTURE, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CLINICAL TRAIL PHASES, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INNOVATIVE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 117. CANADA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 118. CANADA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 119. CANADA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INTRAVITREAL, 2018-2030 (USD MILLION)
TABLE 120. CANADA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 121. CANADA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 122. CANADA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 123. CANADA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 124. CANADA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 125. CANADA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 126. CANADA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 127. CANADA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 128. CANADA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 129. CANADA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PRICING STRUCTURE, 2018-2030 (USD MILLION)
TABLE 130. CANADA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CLINICAL TRAIL PHASES, 2018-2030 (USD MILLION)
TABLE 131. CANADA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INNOVATIVE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 132. MEXICO RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 133. MEXICO RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 134. MEXICO RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INTRAVITREAL, 2018-2030 (USD MILLION)
TABLE 135. MEXICO RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 136. MEXICO RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 137. MEXICO RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 138. MEXICO RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 139. MEXICO RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 140. MEXICO RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 141. MEXICO RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 142. MEXICO RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 143. MEXICO RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 144. MEXICO RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PRICING STRUCTURE, 2018-2030 (USD MILLION)
TABLE 145. MEXICO RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CLINICAL TRAIL PHASES, 2018-2030 (USD MILLION)
TABLE 146. MEXICO RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INNOVATIVE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 147. UNITED STATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 148. UNITED STATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 149. UNITED STATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INTRAVITREAL, 2018-2030 (USD MILLION)
TABLE 150. UNITED STATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 151. UNITED STATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 152. UNITED STATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 153. UNITED STATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 154. UNITED STATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 155. UNITED STATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 156. UNITED STATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 157. UNITED STATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 158. UNITED STATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 159. UNITED STATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PRICING STRUCTURE, 2018-2030 (USD MILLION)
TABLE 160. UNITED STATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CLINICAL TRAIL PHASES, 2018-2030 (USD MILLION)
TABLE 161. UNITED STATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INNOVATIVE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 162. UNITED STATES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 163. ASIA-PACIFIC RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 164. ASIA-PACIFIC RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. ASIA-PACIFIC RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INTRAVITREAL, 2018-2030 (USD MILLION)
TABLE 166. ASIA-PACIFIC RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 167. ASIA-PACIFIC RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 168. ASIA-PACIFIC RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 169. ASIA-PACIFIC RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 170. ASIA-PACIFIC RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 171. ASIA-PACIFIC RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 172. ASIA-PACIFIC RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 173. ASIA-PACIFIC RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 174. ASIA-PACIFIC RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 175. ASIA-PACIFIC RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PRICING STRUCTURE, 2018-2030 (USD MILLION)
TABLE 176. ASIA-PACIFIC RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CLINICAL TRAIL PHASES, 2018-2030 (USD MILLION)
TABLE 177. ASIA-PACIFIC RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INNOVATIVE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 178. ASIA-PACIFIC RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 179. AUSTRALIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 180. AUSTRALIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 181. AUSTRALIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INTRAVITREAL, 2018-2030 (USD MILLION)
TABLE 182. AUSTRALIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 183. AUSTRALIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 184. AUSTRALIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 185. AUSTRALIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 186. AUSTRALIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 187. AUSTRALIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 188. AUSTRALIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 189. AUSTRALIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 190. AUSTRALIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 191. AUSTRALIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PRICING STRUCTURE, 2018-2030 (USD MILLION)
TABLE 192. AUSTRALIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CLINICAL TRAIL PHASES, 2018-2030 (USD MILLION)
TABLE 193. AUSTRALIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INNOVATIVE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 194. CHINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 195. CHINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 196. CHINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INTRAVITREAL, 2018-2030 (USD MILLION)
TABLE 197. CHINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 198. CHINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 199. CHINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 200. CHINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 201. CHINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 202. CHINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 203. CHINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 204. CHINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 205. CHINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 206. CHINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PRICING STRUCTURE, 2018-2030 (USD MILLION)
TABLE 207. CHINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CLINICAL TRAIL PHASES, 2018-2030 (USD MILLION)
TABLE 208. CHINA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INNOVATIVE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 209. INDIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 210. INDIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 211. INDIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INTRAVITREAL, 2018-2030 (USD MILLION)
TABLE 212. INDIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 213. INDIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 214. INDIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 215. INDIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 216. INDIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 217. INDIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 218. INDIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 219. INDIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 220. INDIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 221. INDIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PRICING STRUCTURE, 2018-2030 (USD MILLION)
TABLE 222. INDIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CLINICAL TRAIL PHASES, 2018-2030 (USD MILLION)
TABLE 223. INDIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INNOVATIVE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 224. INDONESIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 225. INDONESIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 226. INDONESIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INTRAVITREAL, 2018-2030 (USD MILLION)
TABLE 227. INDONESIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 228. INDONESIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 229. INDONESIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 230. INDONESIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 231. INDONESIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 232. INDONESIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 233. INDONESIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 234. INDONESIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 235. INDONESIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 236. INDONESIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PRICING STRUCTURE, 2018-2030 (USD MILLION)
TABLE 237. INDONESIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CLINICAL TRAIL PHASES, 2018-2030 (USD MILLION)
TABLE 238. INDONESIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INNOVATIVE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 239. JAPAN RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 240. JAPAN RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 241. JAPAN RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INTRAVITREAL, 2018-2030 (USD MILLION)
TABLE 242. JAPAN RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 243. JAPAN RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 244. JAPAN RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 245. JAPAN RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 246. JAPAN RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 247. JAPAN RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 248. JAPAN RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 249. JAPAN RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 250. JAPAN RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 251. JAPAN RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PRICING STRUCTURE, 2018-2030 (USD MILLION)
TABLE 252. JAPAN RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CLINICAL TRAIL PHASES, 2018-2030 (USD MILLION)
TABLE 253. JAPAN RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INNOVATIVE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 254. MALAYSIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 255. MALAYSIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 256. MALAYSIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INTRAVITREAL, 2018-2030 (USD MILLION)
TABLE 257. MALAYSIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 258. MALAYSIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 259. MALAYSIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 260. MALAYSIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 261. MALAYSIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 262. MALAYSIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 263. MALAYSIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 264. MALAYSIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 265. MALAYSIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 266. MALAYSIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PRICING STRUCTURE, 2018-2030 (USD MILLION)
TABLE 267. MALAYSIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CLINICAL TRAIL PHASES, 2018-2030 (USD MILLION)
TABLE 268. MALAYSIA RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INNOVATIVE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 269. PHILIPPINES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 270. PHILIPPINES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 271. PHILIPPINES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INTRAVITREAL, 2018-2030 (USD MILLION)
TABLE 272. PHILIPPINES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 273. PHILIPPINES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 274. PHILIPPINES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 275. PHILIPPINES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 276. PHILIPPINES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 277. PHILIPPINES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 278. PHILIPPINES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 279. PHILIPPINES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 280. PHILIPPINES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 281. PHILIPPINES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PRICING STRUCTURE, 2018-2030 (USD MILLION)
TABLE 282. PHILIPPINES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CLINICAL TRAIL PHASES, 2018-2030 (USD MILLION)
TABLE 283. PHILIPPINES RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INNOVATIVE TECHNOLOGIES, 2018-2030 (USD MILLION)
TABLE 284. SINGAPORE RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY THERAPY TYPE, 2018-2030 (USD MILLION)
TABLE 285. SINGAPORE RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 286. SINGAPORE RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY INTRAVITREAL, 2018-2030 (USD MILLION)
TABLE 287. SINGAPORE RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 288. SINGAPORE RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, 2018-2030 (USD MILLION)
TABLE 289. SINGAPORE RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 290. SINGAPORE RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 291. SINGAPORE RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY PEDIATRICS, 2018-2030 (USD MILLION)
TABLE 292. SINGAPORE RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY CARE SETTINGS, 2018-2030 (USD MILLION)
TABLE 293. SINGAPORE RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY END USERS, 2018-2030 (USD MILLION)
TABLE 294. SINGAPORE RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY STAGE OF DISEASE, 2018-2030 (USD MILLION)
TABLE 295. SINGAPORE RETINAL DISEASE THERAPY OPTIONS MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 296. SINGAPORE RETINAL DISEASE THERAPY OPTIONS M

Companies Mentioned

  • 4D Molecular Therapeutics
  • Adverum Biotechnologies, Inc.
  • Aerie Pharmaceuticals, Inc. (acquired by Alcon)
  • Alimera Sciences, Inc.
  • Allergan Plc (now part of AbbVie Inc.)
  • Astellas Pharma Inc.
  • Bayer AG
  • Biogen Inc.
  • Clearside Biomedical, Inc.
  • F. Hoffmann-La Roche AG
  • Genentech, Inc. (a member of the Roche Group)
  • Graybug Vision, Inc.
  • Kodiak Sciences Inc.
  • Novartis AG
  • Ohr Pharmaceutical, Inc.
  • Ophthotech Corp.
  • Outlook Therapeutics, Inc.
  • Regenera Pharma Ltd.
  • Regeneron Pharmaceuticals, Inc.
  • Santen Pharmaceutical Co., Ltd.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Retinal Vein Occlusion - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Retinal Vein Occlusion - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 174 Pages
  • Global
From
Retinal Disorder Treatment Market - Global Forecast to 2030 - Product Image

Retinal Disorder Treatment Market - Global Forecast to 2030

  • Report
  • 191 Pages
  • Global
From
Retinal Disorder Treatment - Global Strategic Business Report - Product Image

Retinal Disorder Treatment - Global Strategic Business Report

  • Report
  • 66 Pages
  • Global
From
Retinal Vein Occlusion Treatment Market - Global Forecast to 2030 - Product Image

Retinal Vein Occlusion Treatment Market - Global Forecast to 2030

  • Report
  • 187 Pages
  • Global
From
Retinal Biologics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F - Product Image

Retinal Biologics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • Report
  • 182 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.